Get the Stockscreener App
2.28
0.88%
0.02
Intensity Therapeutics Inc stock is traded at $2.28, with a volume of 3,870.
It is up +0.88% in the last 24 hours and down -0.87% over the past month.
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.
See More
Previous Close:
$2.26
Open:
$2.2
24h Volume:
3,870
Relative Volume:
0.10
Market Cap:
$34.14M
Revenue:
-
Net Income/Loss:
$-16.26M
P/E Ratio:
-1.9299
EPS:
-1.1814
Net Cash Flow:
$-13.50M
1W Performance:
+2.24%
1M Performance:
-0.87%
6M Performance:
-46.35%
1Y Performance:
-37.03%
1-Day Range:
$2.15
$2.29
1-Week Range:
$2.04
$2.3999
52-Week Range:
$1.50
$5.94
Intensity Therapeutics Inc Stock (INTS) Company Profile
Name
Intensity Therapeutics Inc
Sector
Industry
Phone
203-221-7381
Address
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
Compare INTS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INTS
Intensity Therapeutics Inc
|
2.27 | 34.14M | 0 | -16.26M | -13.50M | -1.1814 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.45 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
697.70 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
618.58 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.75 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
268.98 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Intensity Therapeutics Inc Stock (INTS) Latest News
Equillium (NASDAQ:EQ) Stock Quotes, Forecast and News Summary - Benzinga
Intensity Infrastucture Partners Launches Open Season for New Natural Gas Transmission Pipeline to Serve the Bakken Region - Yahoo Finance
Clinical Trials News Live Feed - StockTitan
Drug Monitoring Committee Authorizes Continuation of Intensity T - GuruFocus.com
Intensity Therapeutics' sarcoma trial proceeds after review By Investing.com - Investing.com Canada
Intensity Therapeutics' sarcoma trial proceeds after review - Investing.com India
Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review - Nasdaq
High Intensity Focused Ultrasound Market Forecast and Company Analysis 2025-2033 Featuring Koninklijke Philips, Johnson & Johnson, Hitachi, General Electrics, Medtronic, Stryker, EDAP TMS, Theraclion - Yahoo Finance
vTv Therapeutics (NASDAQ:VTVT) Stock Quotes, Forecast and News Summary - Benzinga
Soft Tissue Sarcoma Market Poised for Significant Growth from - openPR
Soft Tissue Sarcoma Pipeline Review 2024: Clinical Trials - openPR
Alliance Global Partners Initiates Coverage of Intensity Therapeutics (INTS) with Buy Recommendation - MSN
Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6 - PR Newswire
Avoiding Isolation By Volunteering Offers Mental Health Benefits to Seniors - 69News WFMZ-TV
Retrospective Analysis of Dosimetric Comparison Between Intensity-Modulated Radiation Therapy and Volumetric-Modulated Arc Therapy in Patients With Esophageal Cancer - Cureus
Intensity Therapeutics stock hits 52-week low at $1.73 By Investing.com - Investing.com Australia
Intensity Therapeutics stock hits 52-week low at $1.73 - Investing.com
Internal Radiation Therapy - Market.us
Exicure joins hands with GPCR Therapeutics for growth in biotech (NASDAQ:XCUR) - Seeking Alpha
Myelodysplastic Syndrome (MDS) Drugs Market Trends and Sales Forecast to 2030: Total Revenues to Reach US$4.1 Billion Worldwide, with Immunomodulatory Drugs Dominating Shares - GlobeNewswire
Intensity Therapeutics Stock Hits 52-Week Low at $1.76 By Investing.com - Investing.com Australia
Intensity Therapeutics Stock Hits 52-Week Low at $1.76 - Investing.com
Top pharma biotech companies R&D intensity globally 2023 - Statista
Why Is Repare Therapeutics Stock Trading Lower On Friday? - Yahoo Finance
SPR® Therapeutics Recognized as the Fastest Growing Private Company in Northeast Ohio as Part of the Crain’s Fast 50 List - Yahoo Finance
Intensity Therapeutics reports positive results of INT230-6 in breast cancer - Yahoo Finance
Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients - Yahoo Finance
Relay Therapeutics, Inc. (RLAY): A Bull Case Theory - Insider Monkey
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman - Yahoo Finance
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Brea - Yahoo Finance
Intensity Therapeutics Inc Stock (INTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):